Inhibrx Biosciences (INBX) Total Current Liabilities (2023 - 2025)
Historic Total Current Liabilities for Inhibrx Biosciences (INBX) over the last 3 years, with Q3 2025 value amounting to $36.0 million.
- Inhibrx Biosciences' Total Current Liabilities fell 1839.66% to $36.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $36.0 million, marking a year-over-year decrease of 1839.66%. This contributed to the annual value of $40.7 million for FY2024, which is 2767.08% down from last year.
- Per Inhibrx Biosciences' latest filing, its Total Current Liabilities stood at $36.0 million for Q3 2025, which was down 1839.66% from $38.9 million recorded in Q2 2025.
- In the past 5 years, Inhibrx Biosciences' Total Current Liabilities registered a high of $56.3 million during Q4 2023, and its lowest value of $36.0 million during Q3 2025.
- Over the past 3 years, Inhibrx Biosciences' median Total Current Liabilities value was $40.7 million (recorded in 2024), while the average stood at $42.7 million.
- As far as peak fluctuations go, Inhibrx Biosciences' Total Current Liabilities crashed by 2767.08% in 2024, and later decreased by 28.94% in 2025.
- Inhibrx Biosciences' Total Current Liabilities (Quarter) stood at $56.3 million in 2023, then dropped by 27.67% to $40.7 million in 2024, then decreased by 11.65% to $36.0 million in 2025.
- Its Total Current Liabilities stands at $36.0 million for Q3 2025, versus $38.9 million for Q2 2025 and $43.6 million for Q1 2025.